Arrhythmia

>

Latest News

| Image Credit: North American Thrombosis Forum
Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial

January 23rd 2025

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.

5 FDA Decision to Watch for Q1 2025 | Credit: HCPLive.com
5 FDA Decisions to Watch in Q1 2025

December 26th 2024

Oussama Wazni, MD | Credit: HCPLive
Oussama Wazni, MD, MBA: OPTION Trial and the Role of LAAC in Atrial Fibrillation

November 17th 2024

VANISH2: Catheter Ablation Viable First-Line Option for Ventricular Tachycardia | Image Credit: American Heart Association
VANISH2: Catheter Ablation Viable First-Line Option for Ventricular Tachycardia

November 16th 2024

FDA Approves VARIPULSE Platform for Treatment of Atrial Fibrillation | Image Credit: US Food and Drug Administration
FDA Approves VARIPULSE Platform for Treatment of Atrial Fibrillation

November 7th 2024

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.